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Introduction {#sec001}
============

Neurofilament proteins are major constituents of the neuronal cytoskeleton. There are three subunits of neurofilament proteins: the light (NFL), the medium (NFM) and the heavy (NFH) chains. NFL is a putative biomarker of subcortical large-caliber axonal damage. Elevation of NFL levels in body fluid is relevant to not only brain atrophy but also brain diseases \[[@pone.0234519.ref001]\]. For example, for subjects carrying the MAPT, GRN, or C90rf72 genotypes, the concentration of NFL in cerebrospinal fluid (CSF) was increased after the onset of frontotemporal dementia (FTD) \[[@pone.0234519.ref002]\]. Thus, the level of NFL in CSF is a promising biomarker for diagnosing semantic dementia \[[@pone.0234519.ref003]\]. In addition to FTD, CSF NFL was validated as a screening biomarker for inflammatory disease \[[@pone.0234519.ref004]\], Creutzfeldt-Jakob disease (CJD) \[[@pone.0234519.ref005]\], acute neuronal ischemia \[[@pone.0234519.ref006]\], Alzheimer's disease (AD) \[[@pone.0234519.ref001],[@pone.0234519.ref007]\], Parkinson's disease (PD) \[[@pone.0234519.ref008]\], multiple sclerosis (MS) \[[@pone.0234519.ref009]\] and traumatic brain injury \[[@pone.0234519.ref010],[@pone.0234519.ref011]\].

CSF NFL has been validated to be useful for differentiating various types of neurodegenerative diseases. For example, CSF NFL levels were higher in patients with FTD than in early-onset Alzheimer's disease patients \[[@pone.0234519.ref012]\]. CSF NFL was proposed as a biomarker to discriminate CJD from AD, FTD or DLB and to differentiate atypical cases from typical patients for CJD and FTD \[[@pone.0234519.ref013]\]. Therefore, CSF NFL may have an impact on clinical applications for improving diagnostic accuracy for dementia.

Lumbar puncture is necessary for sampling CSF. There are many uncomfortable side effects of lumbar puncture, so it is not easy to perform the CSF NFL assay in clinical practice. Instead of CSF, blood may serve as a promising alternative. However, the concentrations of NFL in blood are extremely low and are hardly detectable using traditional assays. With the development of ultrasensitive assay technologies \[[@pone.0234519.ref014],[@pone.0234519.ref015]\], it has become possible to precisely assay NFL in human plasma. Previously reported results show a significant correlation between plasma and CSF NFL concentrations (ρ \> 0.5, *p* \< 0.001) \[[@pone.0234519.ref016]--[@pone.0234519.ref018]\]. This demonstrates the possibility of evaluating dementia by measuring plasma NFL rather than CSF NFL.

Several independent studies have revealed that the levels of plasma NFL are significantly elevated in patients with mild cognitive impairment (MCI) or AD compared to those in normal controls (NC) \[[@pone.0234519.ref018]--[@pone.0234519.ref020]\]. The AUC (area under receiver operating characteristic curve) value that discriminates MCI/AD from NC according to plasma NFL is higher than 0.8. Increased NFL levels in plasma were associated with reduced Mini-Mental State Examination (MMSE) (r \< -0.3, *p* \< 0.001) \[[@pone.0234519.ref018]--[@pone.0234519.ref020]\], hippocampal volume, and thickness in cortex regions in AD \[[@pone.0234519.ref018]\]. Higher levels of plasma NFL at baseline predicted accelerated declines in these measurements \[[@pone.0234519.ref017],[@pone.0234519.ref018]\]. However, plasma NFL levels are not able to predict conversion to AD in MCI \[[@pone.0234519.ref018],[@pone.0234519.ref019]\].

A recently published paper shows the feasibility of differentiating PD from NC according to plasma NFL (AUC \> 0.7) \[[@pone.0234519.ref021]\]. PD patients at advanced Hoehn-Yohr stages had increased levels of plasma NFL (*p* \< 0.001). Detailed analysis shows that the plasma NFL concentration is modestly correlated with the UPDRS part III (r = 0.42, *p* \< 0.001). A longitudinal study revealed that plasma NFL was able to predict declines in movement and cognition in PD (*p* \< 0.05) \[[@pone.0234519.ref021]\]. Furthermore, the level of plasma NFL could discriminate atypical Parkinsonism syndrome from typical PD (AUC \> 0.8) \[[@pone.0234519.ref016],[@pone.0234519.ref021]\].

These published results demonstrate the possible clinical impacts of the diagnosis of AD or PD using plasma NFL. However, to be approved as a regular medical device for clinical use, the preclinical performance of reagents used for assaying NFL must be characterized according to guidelines issued by Clinical and Laboratory Standards Institute (CLSI). Such characterizations have been truthfully reported for the NFL reagents used in published papers. In this work, the preclinical performance of an NFL reagent used with immunomagnetic reduction is explored. All measurements were conducted according to CLSI guidelines EP5- A3, EP7-A2, EP17-A2, and C28-A2.

Materials and methods {#sec002}
=====================

Synthesis of NFL reagent {#sec003}
------------------------

In the IMR assay, the reagent consisted of antibody-functionalized Fe~3~O~4~ magnetic nanoparticles dispersed in phosphate-buffered saline (PBS) (1x). To achieve the specific association between magnetic nanoparticles and NFL, antibodies (sc20011, Santa Cruz) against NFL were covalently bound to dextran, which acted as an interface between the antibody and the Fe~3~O~4~ cores of the nanoparticles. A detailed description of the binding of the antibody to dextran is given in \[[@pone.0234519.ref022]\]. The mean diameter of the magnetic nanoparticles was 53 nm, as measured by laser dynamic scattering. The concentration of the NFL reagent was 10 mg Fe/ml. The reagent was stored at 4 °C.

IMR measurement {#sec004}
---------------

A mixture of 60 μl of NFL reagent and 60 μl of sample was used for the IMR measurement. A superconducting quantum interference device-based alternative-current magnetic susceptometer (XacPro-S, MagQu) was used to detect the IMR signal of a sample \[[@pone.0234519.ref023]--[@pone.0234519.ref026]\]. During detection of the IMR signal of a sample, two control solutions were used. One was blank, i.e., PBS solution, and the other contained 50 pg/ml NFL (Ab224840, Abcam) in PBS solution.

Exploration of preclinical performance via assay of NFL {#sec005}
-------------------------------------------------------

All experiments were designed and conducted according to the global standards EP5- A3, EP7-A2, EP17-A2, and C28-A2 described by the Clinical & Laboratory Standards Institute (CLSI). Thus, the standard curve, detection limit, assay linearity, dilution recovery range, assay reproducibility, spike recovery, reagent stability, and interference tests were investigated.

Enrollment of subjects {#sec006}
----------------------

Subjects were enrolled at National Taiwan University Hospital and Kaohsiung Chang Gung Memorial Hospital with the approval of the ethics committees of both hospitals. Every participant provided written informed consent. Enrolled subjects were categorized into groups of normal controls (NC) and patients with Parkinson's disease (PD), or PD dementia (PDD), and Alzheimer's disease (AD) according to the inclusion and exclusion criteria listed in [Table 1](#pone.0234519.t001){ref-type="table"}. PD, PDD and AD were combined as patient group. All experimental protocols with human samples were approved by the ethics committees at both hospitals.

10.1371/journal.pone.0234519.t001

###### Exclusion and inclusion criteria used for recruiting normal controls (NC) and subjects with Alzheimer's disease (AD) and Parkinson's disease in this study.

![](pone.0234519.t001){#pone.0234519.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group    Inclusion criteria                                                                                                                                                                                                                                                                                      Exclusion criteria
  -------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NC       1\. Education: at least primary school\                                                                                                                                                                                                                                                                 1\. Subjects with cranial metallic implants, cardiac pacemakers or claustrophobia.\
           2. Age \> 50 years\                                                                                                                                                                                                                                                                                     2. Previous diagnosis of MCI or dementia\
           3. Body weight ≥ 40 kg\                                                                                                                                                                                                                                                                                 3. Significant history of depression\
           4. CDR[\*](#t001fn001){ref-type="table-fn"} = 0\                                                                                                                                                                                                                                                        4. Geriatric Depression Scale \> 8
           5. MMSE[^++^](#t001fn002){ref-type="table-fn"} ≥ 26                                                                                                                                                                                                                                                     

  PD/PDD   1\. Subjects must have symptoms of bradykinesia and at least one of the following: muscular rigidity, resting tremor (4--6 Hz), or postural instability unrelated to primary visual, cerebellar, vestibular or proprioceptive dysfunction \[[@pone.0234519.ref027]\].\                                  1\. Significant history of depression\
           2. Three or more of the following symptoms: unilateral onset, resting tremor, progressive disorder, persistent asymmetry most affecting the side of onset, excellent response to levodopa, severe levodopa-induced chorea, levodopa response for over 5 years, and clinical course of over 10 years.\   2. History of repeated strokes with stepwise progression, repeated head injury, antipsychotic or dopamine-depleting drugs, definite encephalitis and/or oculogyric crises on no drug treatment, negative response to large doses of levodopa (if malabsorption was excluded), strictly unilateral features after 3 years, other neurological features (supranuclear gaze palsy, cerebellar signs, early severe autonomic involvement, Babinski sign, early severe dementia with disturbances of language, memory or praxis), exposure to a known neurotoxin, or presence of cerebral tumor or communicating hydrocephalus according to neuroimaging.
           3. MOCA[^\#^](#t001fn003){ref-type="table-fn"} score greater than 26 for PD with normal cognition\                                                                                                                                                                                                      
           4. MOCA score less than 21 for PD with dementia                                                                                                                                                                                                                                                         

  AD       1\. Subjects must meet the 2011 NIA-AA diagnostic guidelines for probable AD dementia \[[@pone.0234519.ref028]\].\                                                                                                                                                                                      1\. Subjects with cranial metallic implants, cardiac pacemakers or claustrophobia.\
           2. Subjects must have MMSE scores between 10 and 22 and CDR = 0.5 or 1.                                                                                                                                                                                                                                 2. Significant history of depression\
                                                                                                                                                                                                                                                                                                                   3. Geriatric Depression Scale \> 8
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*CDR: Clinical Dementia Ranking

^++^MMSE: Mini-Mental State Examination

^\#^MOCA: Montreal Cognitive Assessment

Preparation of plasma samples {#sec007}
-----------------------------

The blood draw was performed using a 9 ml or 6 ml K3 EDTA lavender-top tube, followed by centrifugation at 1500--2500 g at room temperature for 15 minutes. Five hundred microliters of plasma was aliquoted into each 0.5-ml cryotube and stored at -20 °C or -80 °C. The plasma was required to be frozen no later than 3 hours after the blood draw. Each frozen plasma aliquot was placed in wet ice and then brought to room temperature prior to the IMR measurement.

Statistical methods {#sec008}
-------------------

The continuous variables for each measurement are presented as the means ± standard deviations. The data of NFL concentrations were checked for normality using the Kolmogorov-Smirnov test and the result showed suggested a violation in the normality assumption (*p* = 0.033; data not shown). Therefore, the comparison of NFL concentrations between groups (i.e., normal control vs. disease groups; PD/PDD vs. AD groups) was made using the Mann-Whitney U-test. To clarify the discrimination between two of PD/PDD, AD, patient and NC, receiver operating characteristic (ROC) curve analysis was conducted. The optimal cutoff of NFL concentrations was determined by the Youden index. The confidence interval of area under the curve, sensitivity and specificity was calculated using the DeLong's nonparametric method. At last, the relationship between spiked NFL and measure NFL (both were log10-transformed) was assessed using the Pearson's correlation. A two-sided P value less than 0.5 was considered statistically significant. Analyses were done using GraphPad Prism 5 and MedCalc version 13.

Results {#sec009}
=======

Hook effect on the assay {#sec010}
------------------------

The NFL concentration-dependent IMR signal was investigated. Phosphate-buffered saline (PBS) solutions spiked with NFL (Ab224840, Abcam) at various concentrations were used for the IMR measurements. The concentrations of the spiked NFL samples, denoted as ϕ~NFL~, ranged from 0.001 to 10000 pg/ml. The measured IMR signal, denoted as IMR(%), was 1.967 for 0.001 pg/ml NFL and increased to 4.487 for 10000 pg/ml NFL. The relationship between IMR(%) and ϕ~NFL~ is plotted in [Fig 1](#pone.0234519.g001){ref-type="fig"}. The data points were well fitted to the logistic function $$\text{IMR}\left( \text{\%} \right) = \frac{A - B}{1 + \left( \frac{\phi_{NFL}}{\phi_{o}} \right)^{\gamma}} + B,$$ where A, B, ϕ~o~ and γ were fitting parameters and were found to be 1.840, 4.538, 1.166 and 0.428, respectively. Φ~NFL~ is the spiked NFL concentration in PBS. The fitted logistic curve is plotted as a gray line in [Fig 1](#pone.0234519.g001){ref-type="fig"}. The data point at 10000 pg/ml NFL still lies on the fitted line. This implies that the Hook effect does not occur at 10000 pg/ml NFL.

![Relationship between the IMR signal, IMR(%), and the spiked NFL concentrations.\
The gray solid line is the fitted curve determined with [Eq (1)](#pone.0234519.e001){ref-type="disp-formula"}.](pone.0234519.g001){#pone.0234519.g001}

Assay detection limit {#sec011}
---------------------

The limit of blank (LoB) and the limit of detection (LoD) were investigated according to the guidelines for evaluating the detection capacity of clinical laboratory measurement procedures described in CLSI EP17-A2. The LoB was obtained by determining the appropriate percentile (p) value of the ranked measured concentrations for the blank samples, which was p = 0.95 in this case: $$\text{LoB} = \text{Results}\mspace{720mu}\text{at}\mspace{720mu}\text{position}\mspace{360mu}\left\lbrack {0.95\mspace{360mu}{\text{x}\mspace{720mu}\text{N}}_{\text{B}} + 0.5} \right\rbrack,$$ where N~B~ = 60 (N~B~ is the number of trials) in the current case. [Eq (2)](#pone.0234519.e002){ref-type="disp-formula"} becomes $$\text{LoB} = \text{Results}\mspace{720mu}\text{at}\mspace{720mu}\text{position}\mspace{720mu} 57.5$$

The LoB was calculated by performing linear interpolation using the 57th- and 58th-ranked measured concentrations. [Table 2](#pone.0234519.t002){ref-type="table"} lists the 60 ranked measured concentrations for the PBS samples (blank samples) without NFL. The 57.5th-ranked measured concentration was 0.000 fg/ml. Therefore, the LoB used for assaying NFL with the IMR NFL reagent was 0.000 fg/ml.

10.1371/journal.pone.0234519.t002

###### Ranked list of the 60 measured NFL concentrations for PBS samples not spiked with NFL using the IMR NFL reagent.
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  Rank   Measured concentration (fg/ml)   Rank   Measured concentration (fg/ml)
  ------ -------------------------------- ------ --------------------------------
  1      -0.03                            31     0.00
  2      -0.03                            32     0.00
  3      -0.02                            33     0.00
  4      -0.02                            34     0.00
  5      -0.02                            35     0.00
  6      -0.02                            36     0.00
  7      -0.02                            37     0.00
  8      -0.02                            38     0.00
  9      -0.02                            39     0.00
  10     -0.02                            40     0.00
  11     -0.02                            41     0.00
  12     -0.01                            42     0.00
  13     -0.01                            43     0.00
  14     -0.01                            44     0.00
  15     -0.01                            45     0.00
  16     -0.01                            46     0.00
  17     -0.01                            47     0.00
  18     -0.01                            48     0.00
  19     -0.01                            49     0.00
  20     -0.01                            50     0.00
  21     -0.01                            51     0.00
  22     -0.01                            52     0.00
  23     -0.01                            53     0.00
  24     -0.01                            54     0.00
  25     -0.01                            55     0.00
  26     -0.01                            56     0.00
  27     0.00                             57     0.00
  28     0.00                             58     0.00
  29     0.00                             59     0.00
  30     0.00                             60     0.00

The limit of detection (LoD) was calculated with the equation $$\text{LoD} = \text{LoB} + 1.65\sigma_{\text{S}},$$ where σ~S~ denotes the standard deviation of the measured NFL concentrations of the NFL solutions spiked with a fixed NFL concentration (e.g., 1.0 fg/ml in the current case) in PBS. [Table 3](#pone.0234519.t003){ref-type="table"} lists the measured NFL concentrations of the 60 NFL solutions. The mean value of the 60 measured concentrations was 1.05 fg/ml. The σ~S~ of the 60 measured concentrations was 0.11 fg/ml. The LoD for assaying NFL using IMR was 0.18 fg/ml according to [Eq (4)](#pone.0234519.e004){ref-type="disp-formula"}.

10.1371/journal.pone.0234519.t003

###### Ranked list of the 60 measured NFL concentrations for PBS samples spiked with 1.0 fg/ml NFL using the IMR NFL reagent.
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  Rank   Measured concentration (fg/ml)   Rank   Measured concentration (fg/ml)
  ------ -------------------------------- ------ --------------------------------
  1      0.86                             31     1.06
  2      0.90                             32     1.06
  3      0.91                             33     1.06
  4      0.92                             34     1.06
  5      0.92                             35     1.07
  6      0.93                             36     1.08
  7      0.93                             37     1.08
  8      0.93                             38     1.08
  9      0.93                             39     1.09
  10     0.94                             40     1.09
  11     0.94                             41     1.09
  12     0.94                             42     1.09
  13     0.95                             43     1.09
  14     0.95                             44     1.09
  15     0.96                             45     1.10
  16     0.96                             46     1.10
  17     0.96                             47     1.10
  18     0.97                             48     1.11
  19     0.99                             49     1.11
  20     0.99                             50     1.12
  21     1.00                             51     1.13
  22     1.01                             52     1.14
  23     1.01                             53     1.14
  24     1.03                             54     1.17
  25     1.05                             55     1.20
  26     1.05                             56     1.20
  27     1.05                             57     1.21
  28     1.05                             58     1.31
  29     1.05                             59     1.38
  30     1.05                             60     1.41

Assay linearity {#sec012}
---------------

The linear range of the NFL assay is defined according to the NFL concentrations that reflect the proportionality between the measured NFL concentration ϕ~NFL,m~ and the spiked NFL concentration ϕ~NFL~. The proportional coefficient should be between 0.9 and 1.1, and the coefficient of determination R^2^ for the ϕ~NFL,m~-ϕ~NFL~ curve should be higher than 0.95. To investigate the assay linearity, the detected IMR (%) values in [Fig 1](#pone.0234519.g001){ref-type="fig"} were converted to the measured NFL concentrations ϕ~NFL,m~ via [Eq (1)](#pone.0234519.e001){ref-type="disp-formula"}. [Fig 2](#pone.0234519.g002){ref-type="fig"} plots the relationship between ϕ~NFL,m~ and ϕ~NFL~. It was found that ϕ~NFL,m~ is proportional to ϕ~NFL~, as expressed by $$\phi_{\text{NFL},\text{m}} = \text{s}\phi_{\text{NFL}}$$

![Relationship between the measured NFL concentrations using IMR and the spiked NFL concentrations.\
The solid/dotted/dashed lines show the proportionalities between the measured NFL concentrations and the spiked NFL concentrations according to various ranges of spiked NFL concentrations.](pone.0234519.g002){#pone.0234519.g002}

The proportional coefficient s depends on the selected ranges of NFL concentrations. For example, for the selected NFL concentration range from 0.001 to 10000 pg/ml, s and R^2^ are equal to 1.17 and 0.9998, respectively, according to the plotted gray dotted line in [Fig 2](#pone.0234519.g002){ref-type="fig"}. In this case, the proportional coefficient is higher than 1.1, which does not meet the requirement of the linear range. The data of the highest concentration to the lowest concentration are removed to find s in [Eq (5)](#pone.0234519.e005){ref-type="disp-formula"}, i.e., 0.001 to 1000 pg/ml or 0.01 to 10000 pg/ml. The results show that s is 1.02 and R^2^ is 0.9999 once the concentration range is selected to be from 0.001 to 1000 pg/ml, according to the plotted solid line in [Fig 2](#pone.0234519.g002){ref-type="fig"}. Therefore, the linear range for the NFL assay using the IMR NFL reagent ranges from 0.001 to 1000 pg/ml.

Dilution recovery range {#sec013}
-----------------------

The dilution recovery is defined as $$\text{Dilution}\mspace{720mu}\text{recovery} = \frac{\text{measured}\mspace{720mu}\text{concentration}\mspace{720mu}\text{after}\mspace{720mu}\text{dilution}}{\text{expected}\mspace{720mu}\text{concentration}\mspace{720mu}\text{after}\mspace{720mu}\text{dilution}}x100\%$$

The acceptable dilution recovery range is from 90% to 110%. In this work, an NFL solution with a measured concentration of 101.87 pg/ml was diluted by a factor of between 2 and 100 with PBS solution. The expected and measured NFL concentrations after dilution are listed in [Table 4](#pone.0234519.t004){ref-type="table"}. The dilution recoveries of the 2X- to 100X-diluted samples ranged from 1001.1% to 105.2%, which are within the acceptable dilution recovery range. Hence, the sample used for the IMR NFL assay could be diluted up to 100 times.

10.1371/journal.pone.0234519.t004

###### Dilution factors, expected concentrations, measured concentrations, and dilution recovery of diluted samples used in the tests of the dilution recovery range for assaying NFL using the IMR NFL reagent.

![](pone.0234519.t004){#pone.0234519.t004g}

  Dilution factor   Expected concentration (pg/ml)   Measured concentration (pg/ml)   Dilution recovery
  ----------------- -------------------------------- -------------------------------- -------------------
  2X                50.93                            52.63                            103.3%
  5X                20.37                            20.43                            100.3%
  10X               10.19                            10.56                            103.7%
  20X               5.09                             5.36                             105.2%
  50X               2.04                             2.11                             103.5%
  100X              1.02                             1.03                             101.1%

Spiked recovery {#sec014}
---------------

A sample with a higher NFL concentration was spiked into another sample with a lower NFL concentration. The NFL concentration of the mixture was assayed with IMR NFL reagent. The spiked recovery was calculated via $$\text{Spiked}\mspace{720mu}\text{recovery} = \frac{\text{measured}\mspace{720mu}\text{concentration}\mspace{720mu}\text{after}\mspace{720mu}\text{mixing}}{\text{expected}\mspace{720mu}\text{concentration}\mspace{720mu}\text{after}\mspace{720mu}\text{mixing}}x100\%$$

Two plasma samples with original concentrations of 5.39 (plasma sample no. PRA) and 101.09 pg/ml (plasma sample no. PRF) were mixed at various volume ratios, as shown in [Table 5](#pone.0234519.t005){ref-type="table"}. The original concentrations were assayed using IMR NFL reagent. The results in [Table 5](#pone.0234519.t005){ref-type="table"} reveal that the spiked recovery ranged from 93.4% to 99.1% for the IMR NFL reagent.

10.1371/journal.pone.0234519.t005

###### Measured NFL concentration using the IMR NFL reagent and the spiked recovery of plasma samples.
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  Plasma sample No.   Volume ratio (PRA:PRF)   Original concentration (pg/ml)   Expected concentration (pg/ml)   Measured concentration (pg/ml)   Spiked recovery
  ------------------- ------------------------ -------------------------------- -------------------------------- -------------------------------- -----------------
  PRA                 \-                       5.39                             \-                               \-                               \-
  PRB                 80%:20%                  \-                               24.53                            22.91                            93.4%
  PRC                 60%:40%                  \-                               43.67                            41.41                            94.8%
  PRD                 40%:60%                  \-                               62.81                            62.27                            99.1%
  PRE                 20%:80%                  \-                               81.95                            80.22                            97.0%
  PRF                 \-                       101.09                           \-                               \-                               \-

Assay reproducibility {#sec015}
---------------------

The reproducibility of the NFL assay with IMR was investigated according to CLSI EP5-A3: Approved Guidelines for Evaluation of the Precision Performance of Quantitative Measurement Methods. The NFL solutions were measured precisely in one run using IMR NFL reagent. Two sequential measurements of two duplicate measurements each were regarded as two runs, referred to as Run1 and Run2. Two PBS solutions spiked with different NFL concentrations were used for the tests of reproducibility. The measured NFL concentrations are listed in [Table 6](#pone.0234519.t006){ref-type="table"} for NFL-PBS sample 1 and in [Table 7](#pone.0234519.t007){ref-type="table"} for NFL-PBS sample 2. The results show that NFL-PBS sample 1 had a concentration of 1.00 pg/ml, and NFL-PBS sample 2 had a concentration of 100.17 pg/ml. By following the statistical method described in the CLSI EP5-A3 guidelines, the within-lab precision and standard deviations of repeatability for NFL-PBS samples 1 and 2 were calculated and are listed in [Table 8](#pone.0234519.t008){ref-type="table"}. The imprecision (%CV) of the NFL assay using the IMR NFL reagent was less than 10%.

10.1371/journal.pone.0234519.t006

###### Measured NFL concentrations (listed in the Result11, Result12, Result21 and Result22 columns) in NFL-PBS sample 1 used for the analysis of the precision and reproducibility of the IMR NFL reagent.
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  Run 1   Run 2       ΔMean   Mean (pg/ml)                                                                           
  ------- ----------- ------- -------------- ------ ------- ---- ----------- ------- ------- ------- ------- ------- -------
  1       2019/7/24   1.04    1.00           1.02   0.002   2    2019/7/29   0.995   1.097   1.046   0.010   0.001   1.03
  3       2019/7/31   1.011   1.008          1.01   0.000   4    2019/8/1    1.018   1.002   1.010   0.000   0.000   1.01
  5       2019/8/2    0.964   1.010          0.99   0.002   6    2019/8/6    1.000   1.020   1.010   0.000   0.001   1.00
  7       2019/8/7    1.018   0.992          1.01   0.001   8    2019/8/13   0.995   0.995   0.995   0.000   0.000   1.00
  9       2019/8/14   1.012   0.990          1.00   0.000   10   2019/8/21   0.950   0.980   0.965   0.001   0.001   0.98
  11      2019/8/27   1.015   1.020          1.02   0.000   12   2019/8/30   1.010   1.010   1.010   0.000   0.000   1.01
  13      2019/9/3    1.010   0.972          0.99   0.001   14   2019/9/4    0.985   1.010   0.998   0.001   0.000   0.99
  15      2019/9/5    0.995   1.005          1.00   0.000   16   2019/9/9    0.995   1.025   1.010   0.001   0.000   1.01
  17      2019/9/10   1.005   1.000          1.00   0.000   18   2019/9/12   0.970   0.975   0.973   0.000   0.001   0.99
  19      2019/9/17   1.005   1.010          1.01   0.000   20   2019/9/18   0.980   0.990   0.985   0.000   0.001   1.00
  Sum                                               0.007                                            0.013   0.004   10.02

Mean1 = (Result11+Result12)/2 ΔResult1 = (Result11-Result12)\^2

Mean2 = (Result21+Result22)/2 ΔResult2 = (Result21-Result22)\^2

ΔMean = (Mean1-Mean2)\^2   Mean = (Mean1+Mean2)/2

10.1371/journal.pone.0234519.t007

###### Measured NFL concentrations (listed in the Result11, Result12, Result21 and Result22 columns) in NFL-PBS sample 2 used for the analysis of the precision and reproducibility of the IMR NFL reagent.
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  Run1   Run2        ΔMean     Mean (pg/ml)                                                                                    
  ------ ----------- --------- -------------- -------- ------- ---- ----------- --------- --------- --------- -------- ------- ---------
  1      2019/7/24   99.51     100.31         99.91    0.640   2    2019/7/29   100.735   99.625    100.180   1.232    0.073   100.05
  3      2019/7/31   100.245   100.085        100.17   0.026   4    2019/8/1    99.780    99.375    99.578    0.164    0.345   99.87
  5      2019/8/2    99.820    99.655         99.74    0.027   6    2019/8/6    99.865    99.710    99.788    0.024    0.002   99.76
  7      2019/8/7    99.975    99.975         99.98    0.000   8    2019/8/13   100.835   99.630    100.233   1.452    0.066   100.10
  9      2019/8/14   99.945    100.075        100.01   0.017   10   2019/8/21   100.195   99.830    100.013   0.133    0.000   100.01
  11     2019/8/27   100.315   100.465        100.39   0.023   12   2019/8/30   99.615    100.390   100.003   0.601    0.150   100.20
  13     2019/9/3    99.915    100.035        99.98    0.014   14   2019/9/4    104.440   100.350   102.395   16.728   5.856   101.19
  15     2019/9/5    100.440   99.770         100.11   0.449   16   2019/9/9    100.500   100.110   100.305   0.152    0.040   100.21
  17     2019/9/10   99.905    99.925         99.92    0.000   18   2019/9/12   99.570    100.485   100.028   0.837    0.013   99.97
  19     2019/9/17   100.250   101.895        101.07   2.706   20   2019/9/18   99.760    99.405    99.583    0.126    2.220   100.33
  Sum                                                  3.902                                                  21.449   8.766   1001.68

Mean1 = (Result11+Result12)/2 ΔResult1 = (Result11-Result12)\^2

Mean2 = (Result21+Result22)/2 ΔResult2 = (Result21-Result22)\^2

ΔMean = (Mean1-Mean2)\^2   Mean = (Mean1+Mean2)/2

10.1371/journal.pone.0234519.t008

###### Standard deviations of the repeatability and within-lab precision for the assay of NFL concentrations in PBS using the IMR NFL reagent.

The samples used show mean measured NFL concentrations of 1.00 pg/ml and 100.17 pg/ml. The coefficient of variation is the ratio of the standard deviation and the mean of the measured NFL concentrations.
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  Material           Mean of measured NFL concentrations   Standard deviation (Coefficient of variation)   
  ------------------ ------------------------------------- ----------------------------------------------- ---------------------
  NFL-PBS sample 1   1.00 pg/ml                            0.027 pg/ml (2.67%)                             0.019 pg/ml (1.89%)
  NFL-PBS sample 2   100.17 pg/ml                          0.528 pg/ml (0.53%)                             1.313 pg/ml (1.31%)

Interference test {#sec016}
-----------------

Possible false signals during the measurement of NFL concentrations due to molecules referred to as interfering materials in the tested sample were investigated. [Table 9](#pone.0234519.t009){ref-type="table"} lists all the interfering materials tested in this work. Sample No. 1 was pure PBS solution spiked only with 100 pg/ml NFL without any interfering material. The measured NFL concentration of Sample No. 1 (= 99.35 pg/ml) was used as a reference. The recovery rate of a given sample (Sample No. 2--17) was the ratio of the measured NFL concentration of the given sample to that of the reference sample. The recovery rate ranged from 93.4% to 106.4%, which satisfied the requirement for nonsignificant interference in the NFL assay. The results show that the molecules listed in [Table 9](#pone.0234519.t009){ref-type="table"}, including NF heavy and medium peptides, did not significantly interfere with the NFL assay using the IMR NFL reagent.

10.1371/journal.pone.0234519.t009

###### Materials and their concentrations used for interference tests for the NFL assay utilizing the NFL reagent with IMR.

The concentration of NFL in each sample was 100 pg/ml. The matrix was PBS solution. The measured NFL concentrations of each sample are listed. Using the NFL concentration of the pure NFL-PBS sample (sample No. 1) as a reference, the recovery rates of the NFL concentrations of the other samples were calculated and are listed in the rightmost column.
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  Sample No.   Interfering material             Concentration   Measured NFL concentration (pg/ml)   Recovery rate
  ------------ -------------------------------- --------------- ------------------------------------ ---------------
  1            None                             \-              99.35                                \-
  2            Conjugated bilirubin             600 μg/ml       96.16                                96.8%
  3            Hemoglobin                       10000 μg/ml     105.46                               106.2%
  4            Intralipid                       30000 μg/ml     97.03                                97.7%
  5            Albumin                          60000 μg/ml     92.77                                93.4%
  6            Rheumatoid factor                500 IU/ml       96.30                                96.9%
  7            Uric acid                        200 μg/ml       100.92                               101.6%
  8            Neurofilament, Heavy peptide     100 pg/ml       101.29                               102.0%
  9            Neurofilament, Medium peptide    100 pg/ml       105.69                               106.4%
  10           Acetylsalicylic acid             500 μg/ml       97.06                                97.7%
  11           Ascorbic acid                    300 μg/ml       97.35                                98.0%
  12           Ampicillin sodium                1000 μg/ml      101.21                               101.9%
  13           Quetiapine fumarate              100 μg/ml       100.87                               101.5%
  14           Galantamine hydrobromide         90 ng/ml        98.23                                98.9%
  15           Rivastigmine hydrogen tartrate   100 ng/ml       96.36                                97.0%
  16           Donepezil hydrochloride          1000 ng/ml      100.44                               101.1%
  17           Memantine hydrochloride          150 ng/ml       102.75                               103.4%

Plasma NFL concentrations in patients with dementia {#sec017}
---------------------------------------------------

In this work, thirty-one normal controls (NC), fifty-two patients with Parkinson's disease (PD) or PD dementia (PDD), and thirty-one patients with Alzheimer's disease (AD) were enrolled at National Taiwan University Hospital and Kaohsiung Chang Gung Memorial Hospital. The demographic information of the subjects is listed in [Table 10](#pone.0234519.t010){ref-type="table"}. NCs had a mean level of 7.70 ± 4.00 pg/ml for plasma NFL. Patient group showed 66.8 ± 10.3 pg/ml for plasma NFL level, which is significantly higher than NCs (*p* \< 0.001), as shown in [Fig 3(A)](#pone.0234519.g003){ref-type="fig"}. A significant difference in the plasma NFL concentrations between AD (19.24 ± 8.99 pg/ml) and PD/PDD (15.85 ± 7.82 pg/ml) (*p* \< 0.05) was found.

![(A) Measured NFL concentrations in human plasma using IMR and (B) ROC curves used for differentiating various diagnostic groups (NC: Normal control, PD: Parkinson's disease, PDD: Parkinson's disease dementia, AD: Alzheimer's disease, dementia: PD/PDD+AD).\
The horizontal line represents median and the range of error bar represents interquartile range.](pone.0234519.g003){#pone.0234519.g003}

10.1371/journal.pone.0234519.t010

###### Brief demographic information for the enrolled subjects.
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  Group (n)     NC (31)       Patient (83)[\*](#t010fn001){ref-type="table-fn"}   PD/PDD (52)    AD (31)
  ------------- ------------- --------------------------------------------------- -------------- --------------
  Female%       80.0          56.5                                                61.7           48.0
  Age (years)   60.3 ± 7.2    66.8 ± 10.3                                         62.6 ± 9.5     74.6 ± 9.6
  MMSE          28.0 ± 1.9    23.2 ± 5.3                                          24.8 ± 4.6     20.2 ± 5.3
  H-Y stage     \-            \-                                                  1.96 ± 0.98    \-
  NFL (pg/ml)   7.70 ± 4.00   17.11 ± 8.39                                        15.85 ± 7.82   19.24 ± 8.99

\*: Patient includes PD/PDD and AD NC: normal control PD: Parkinson's disease

PDD: Parkinson's disease dementia AD: Alzheimer's disease

MMSE: Mini-Mental State Examination

H-Y stage: Hoehn and Yahr stage

By using the ultrasensitive and highly specific IMR NFL assay, the clear discrimination of the concentrations of plasma NFL in NCs (7.70 ± 4.00 pg/ml) and PD/PDD patients (15.85 ± 7.82 pg/ml) was achieved (*p* \< 0.001). Through the analysis of the receiver operating characteristic (ROC) curve plotted with the black solid line in [Fig 3(B)](#pone.0234519.g003){ref-type="fig"}, the cut-off value of the plasma NFL concentration used to discriminate PD/PDD patients from NCs was found to be 12.71 pg/ml, which resulted in values of 0.712 and 0.903 for clinical sensitivity and specificity, respectively. The corresponding area under the curve (AUC) was 0.838, as shown in [Table 11](#pone.0234519.t011){ref-type="table"}. These results reveal the feasibility of differentiating PD/PDD patients from normal controls.

10.1371/journal.pone.0234519.t011

###### Results of the ROC curve analysis using plasma NFL concentrations as a discriminative index.
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  ROC curve analysis                                    Cut-off value of the plasma NFL concentration (pg/ml)   Sensitivity (95% CI)   Specificity (95% CI)   AUC (95% CI)
  ----------------------------------------------------- ------------------------------------------------------- ---------------------- ---------------------- ----------------------
  NC vs. PD/PDD                                         12.71                                                   0.712 (0.569--0.829)   0.903 (0.743--0.980)   0.838 (0.754--0.921)
  NC vs. AD                                             12.04                                                   0.838 (0.663--0.946)   0.871 (0.702--0.964)   0.919 (0.855--0.984)
  NC vs. Patient[\*](#t011fn002){ref-type="table-fn"}   12.71                                                   0.735 (0.627--0.826)   0.903 (0.743--0.980)   0.868 (0.803--0.933)
  PD/PDD vs. AD                                         18.02                                                   0.613 (0.422--0.782)   0.654 (0.509--0.780)   0.630 (0.507--0.753)

ROC: receiver operating characteristic AUC: area under the curve

\*: including PD/PDD and AD NC: normal control PD: Parkinson's disease

PDD: Parkinson's disease dementia AD: Alzheimer's disease

In addition to PD/PDD patients, AD patients (19.24 ± 8.99 pg/ml) showed higher levels of plasma NFL than NCs (*p* \< 0.001). The ROC curve for differentiating AD patients from NCs using plasma NFL concentrations is plotted with the gray solid line in [Fig 3(B)](#pone.0234519.g003){ref-type="fig"}. The cut-off value (= 12.04 pg/ml), sensitivity (= 0.838), specificity (= 0.871) and AUC (= 0.919) values are listed in [Table 12](#pone.0234519.t012){ref-type="table"}. Notably, the accuracy of differentiating AD patients from NCs was higher than 85%. By combining PD/PDD and AD into a patient group, discrimination between patient and NCs using plasma NFL concentrations was investigated. The ROC curve is plotted as the black dashed line in [Fig 3(B)](#pone.0234519.g003){ref-type="fig"}. The cut-off value of the plasma NFL concentration used to discriminate patient from NCs is 12.71 pg/ml, the sensitivity is 0.735, the specificity is 0.903 and the AUC is 0.868. These results demonstrate the feasibility of identifying PD/PDD or AD using plasma NFL concentrations. This was also shown by other clinical studies listed in [Table 12](#pone.0234519.t012){ref-type="table"} \[[@pone.0234519.ref001],[@pone.0234519.ref016],[@pone.0234519.ref020],[@pone.0234519.ref021],[@pone.0234519.ref029]\]. However, differentiation between AD and PD/PDD patients using plasma NFL concentrations was not as accurate because the AUC is 0.630. This suggests that the plasma NFL concentration is not suitable for differential diagnosis between AD and PD/PDD. Alternatively, plasma NFL concentrations could be a promising biomarker for screening for neurodegenerative diseases.

10.1371/journal.pone.0234519.t012

###### Clinical sensitivity and specificity of the under the curve (AUC) value for discriminating PD/PDD or AD patients from NCs according to NFL concentrations in blood.
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  Control (n)   Patient (n)            Sample   Sensitivity   Specificity   AUC     Ref.
  ------------- ---------------------- -------- ------------- ------------- ------- -----------
  NC (31)       PD/PDD (52)            Plasma   0.712         0.903         0.838   This work
  NC (26)       PD (20)                Plasma   0.82          0.92          \-      16
  NC (40)       PD/PDD (116)           Plasma   0.532         0.905         0.754   21
  NC (52)       PD/PDD (139)           Serum    0.61          0.68          0.64    29
  NC (31)       AD (31)                Plasma   0.838         0.871         0.919   This work
  NC (193)      MCI (197) + AD (180)   Plasma   \-            \-            0.87    1
  NC (41)       aMCI (25) + ADD (33)   Plasma   0.84          0.78          0.92    20

NC: normal control PD: Parkinson's disease

PDD: Parkinson's disease dementia AD: Alzheimer's disease

aMCI: amnesic mild cognitive impairment

Discussion {#sec018}
==========

In this work, the reagent for assaying NFL while utilizing the IMR platform showed ultrasensitive detection at a sub-fg/ml concentration. According to published papers, several assay platforms, such as enzyme-linked immunosorbent assay (ELISA) \[[@pone.0234519.ref030]--[@pone.0234519.ref033]\], single-molecule assay (SIMOA) \[[@pone.0234519.ref018],[@pone.0234519.ref034]\] or electrochemiluminescence (ECL) \[[@pone.0234519.ref035]\], have been utilized to detect NFL. The reported limits of detection (LoDs) in representative works are listed in [Table 13](#pone.0234519.t013){ref-type="table"}. Depending on the antibodies used, a given assay platform might show various LoDs. Roughly speaking, ECL is more sensitive than ELISA but less sensitive than SIMOA. All three assay platforms show sensitivity at a level of pg/ml or higher in terms of the LoDs for assaying NFL. However, IMR shows a LoD of sub-fg/ml for assaying NFL. This evidence indicates that the IMR assay is much more sensitive than either ELISA, SIMOA or ECL by at least 1000-fold. Notably, the results of interference tests shown in [Table 9](#pone.0234519.t009){ref-type="table"} reveal the high specificity of assaying NFL with IMR. Thus, the IMR NFL assay is not only ultrasensitive but also specific.

10.1371/journal.pone.0234519.t013

###### Limits of detection (LoDs) reported for various assay platforms, such as enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence (ECL) and single-molecule assay (SIMOA).
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  Assay platform   LoD          Ref.
  ---------------- ------------ -----------
  ELISA            15.6 pg/ml   30
  ELISA            5 pg/ml      31
  ELISA            125 pg/ml    32
  ELISA            250 pg/ml    33
  SIMOA            0.97 pg/ml   34
  SIMOA            2.2 pg/ml    18
  ECL              15.6 pg/ml   35
  IMR              0.18 fg/ml   This work

The reasons for achieving ultrasensitive and highly specific IMR assays have been discussed in previous works \[[@pone.0234519.ref036],[@pone.0234519.ref037]\]. There are three key factors involved in achieving high sensitivity and specificity for the IMR assay. One is the utilization of antibody-functionalized magnetic nanoparticles homogeneously suspended in liquid. The surfaces of these magnetic nanoparticles serve as substrates of antibodies to catch target antigens. The total area of the association between antibodies and antigens in the IMR assay is obviously larger than that ELISA or ECL.

Another key factor is the use of the ultrasensitive sensor to detect the tiny reductions in magnetic signals due to the associations between antibodies and antigens. The adopted sensor is a high-temperature superconducting quantum interference device (SQUID) magnetometer. The noise level of the SQUID magnetometer is on the order of approximately fT/√Hz. The magnetic signal generated by core Fe~3~O~4~ magnetic nanoparticles that are 35 nm in diameter is approximately 1 pT/√Hz \[[@pone.0234519.ref036]\]. This means that, in principle, the change in the magnetic signal due to a single magnetic nanoparticle can be detected. Notably, a sample with an ultralow concentration has an extremely low number of target antigens. After mixing the sample with IMR reagent, only a few magnetic nanoparticles can bind with the target antigen. The reduction in the magnetic signal of the reagent would be very small. As described, the SQUID magnetometer is sensitive enough to detect the tiny reduction in the magnetic signal.

The other factor is the so-called "spin-wash" mechanism involved in IMR \[[@pone.0234519.ref037]\]. Once a biomolecule binds with the antibody on a magnetic nanoparticle, the bound biomolecule experiences a centrifugal force because the nanoparticle is rotating. The specific biomolecule shows a stronger binding force with the antibody than the nonspecific biomolecule. By controlling the rotating frequency of the nanoparticles adequately, the strength of the centrifugal force can be made stronger than that of nonspecific binding but weaker than that of specific binding. Hence, nonspecific binding is significantly suppressed. Remarkably, the specificity of the antibody against NFL also plays a role in the "spin-wash" mechanism. Therefore, due to these three key factors, IMR shows merits of high sensitivity and high specificity in assaying NFL.

Conclusion {#sec019}
==========

An assay kit for the measurement of NFL utilizing immunomagnetic reduction was developed. The preclinical characterizations performed according to CLSI guidelines revealed that the IMR NFL assay is ultrasensitive, highly specific and reliable. By applying the IMR NFL kit for assaying plasma NFL in NCs and PD/PDD and AD patients, an accuracy higher than 80% in discriminating PD/PDD or AD patients from NCs was shown. However, the concentrations of plasma NFL are not suitable for differentiating PD/PDD from AD.
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Comment \#2: Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate \"supporting information\" files

Response \#2: Tables have been integrated into the main body of the manuscript.

Comment \#3: PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

Response \#3: The corresponding author, Shieh-Yueh Yang, has an ORCID ID: 0000-0002-7850-4597.

Comment \#4:　Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Response \#4: Done.

Comment \#5: Please also include the following statement within your amended Funding Statement. "The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

Response \#5: Done.

Comment \#6: Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Response \#6: "MagQu Co., Ltd. and MagQu LLC do not alter our adherence to PLOS ONE policies on sharing data and materials." is added into the revised manuscript.

Comment \#7: Please include both an updated Funding Statement and Competing Interests Statement in your cover letter.

Response \#7: Done.

Comment \#8: The authors give a brief description of the statistical analyses that were employed, but they did not describe the analyses used to ascertain the diagnostic accuracy of their NFL assay. They report sensitivity, specificity, and AUC values, but it is unclear what statistical tests were used to derive these values.

Response \#8: We thank reviewers for your comments. We have re-written the statistics subsection in the revised manuscript.

In addition, the following sentences are added in the statistics subsection for the tests of sensitivity, specificity and AUC:

"To discriminate PD/PDD (or AD) patients from NCs, receiver operating characteristic (ROC) curve analysis was conducted. The optimal cutoff of NFL concentrations was determined by the Youden index. The confidence interval of area under the curve, sensitivity and specificity was calculated using the DeLong's nonparametric method."

Comment \#9: The authors also state that t-tests were used to compare continuous variables, but it is unclear what comparisons they are referring to. This statement is very vague as it is unclear if the authors are referring to paired t-tests for the reproducibility studies or whether they used a series a two-sample t-tests for the clinical group comparisons. If two-sample t-tests were used for the clinical group comparisons, this would be an incorrect approach. When comparing three or more groups, a one-way ANOVA should be used so that the groups are compared simultaneously and so that the p-values of groupwise comparisons that are statistically significant are adjusted for multiple comparisons.

Response \#9: The following sentences are added in the statistics subsection in the revised manuscript to clarify we were only interested in comparing normal control to disease groups and PD/PDD to AD groups:

"The data of NFL concentrations were checked for normality using the Kolmogorov-Smirnov test and the result showed suggested a violation in the normality assumption (p = 0.033; data not shown). Therefore, the comparison of NFL concentrations between groups (i.e., normal control vs. disease groups; PD/PDD vs. AD groups) was made using the Mann-Whitney U-test."

The demographic information about Patient, including PD/PDD and AD, is added in Table 10 in the revised manuscript.

Comment \#10: Did the authors check to ensure that the distribution of NFL values met the normality assumption? If they are not normally distributed, then non-parametric tests should be used to test group differences.

Response \#10: We found the NFL values violate the normality assumption. Therefore, we used Mann-Whitney U-test when comparing groups. The following sentences to illustrate this point are added in Statistics subsection:

"The data of NFL concentrations were checked for normality using the Kolmogorov-Smirnov test and the result showed suggested a violation in the normality assumption (P = 0.033; data not shown). Therefore, the comparison of NFL concentrations between groups (i.e., normal control vs. disease groups; PD/PDD vs. AD groups) was made using the Mann-Whitney U-test."

Meanwhile, the Figure 3A is also revised.

Comment \#11: Why did the authors report the diagnostic accuracy results in the Discussion section? This information should be included in the "Plasma NFL concentrations in patients with dementia" section. In addition, I emphasize the need to describe the statistical methods that were used to derive the AUC values, sensitivity, and specificity. Were these from a logistic regression model or a specific ROC function. Which of the stated statistical software packages were used for these analyses?

Response \#11: The diagnostic accuracy results have been moved to "Plasma NFL concentrations in patients with dementia". The detailed information about statistics is described in Statistics subsection in the revised manuscript.

Comment \#12: For AUC, sensitivity, and specificity, please report 95% confidence intervals with these values

Response \#12: The values with 95% CI are added in Table 11.

Comment \#13: Although clear differences in plasma NFL concentrations were observed among NCs and PD and AD patients, these diagnostic cut-off values should be validated in another group of more patients in further studies

Response \#13: Thank for the valuable suggestion. We will do the validation by enrolling independent cohorts in the near future.

###### 

Submitted filename: Response-R1.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0234519.r003

Decision Letter 1

Chen

Kewei

Academic Editor

© 2020 Kewei Chen

2020

Kewei Chen

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

28 May 2020

Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology

PONE-D-20-04529R1

Dear Dr. Yang,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Kewei Chen, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have addressed all of my comments sufficiently and no further revisions are required for this manuscript.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Michael Malek-Ahmadi
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Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology

Dear Dr. Yang:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Kewei Chen

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**Huei-Chun Liu, Chin-Yi Lin and Shieh-Yueh Yang are employees at MagQu Co., Ltd. Shieh-Yueh Yang is also an employee of MagQu LLC. Shieh-Yueh Yang owns stock in MagQu Co., Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
